OOIR: Observatory of International Research

Papers

(The H4-Index of Molecular Therapy-Oncolytics is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Lazertinib improves the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 overexpression cancer cells in vitro, in vivo, and ex vivo	199
Efficacy of a third-generation oncolytic herpes simplex virus in refractory soft tissue sarcoma xenograft models	152
Ferroptosis gene signature in cholangiocarcinoma	96
esRAGE-expressing oHSV enhances anti-tumor efficacy by inhibition of endothelial cell activation	72
Targeting carcinoembryonic antigen-expressing tumors using a novel transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1	72
Spatiotemporal analysis of induced neural stem cell therapy to overcome advanced glioblastoma recurrence	69
Promoting role of pentraxin-3 in esophageal squamous cell carcinoma	61
Metabolic remodeling in tumor-associated macrophages contributing to antitumor activity of cryptotanshinone by regulating TRAF6-ASK1 axis	54
Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma	52
Synthetic mRNA-based gene therapy for glioblastoma: TRAIL-mRNA synergistically enhances PTEN-mRNA-based therapy	49
Anti-CAIX BBζ CAR4/8 T cells exhibit superior efficacy in a ccRCC mouse model	46
Reinvigoration of innate and adaptive immunity via therapeutic cellular vaccine for patients with AML	45
A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers	45
Cancer stem/progenitor signatures refine the classification of clear cell renal cell carcinoma with stratified prognosis and decreased immunotherapy efficacy	42
Oncolytic herpes simplex virus armed with a bacterial GBP1 degrader improves antitumor activity	40
The miR-23a/27a/24-2 cluster promotes postoperative progression of early-stage non-small cell lung cancer	39
Circular RNA circLAMA3 inhibits the proliferation of bladder cancer by directly binding an mRNA	38
PROTACs in gastrointestinal cancers	36
In vivo DNA-launched bispecific T cell engager targeting IL-13Rα2 controls tumor growth in an animal model of glioblastoma multiforme	35
CAFs/tumor cells co-targeting DNA vaccine in combination with low-dose gemcitabine for the treatment of Panc02 murine pancreatic cancer	35
Potential for reversing miR-634-mediated cytoprotective processes to improve efficacy of chemotherapy against oral squamous cell carcinoma	35
Replication-incompetent influenza A viruses armed with IFN-γ effectively mediate immune modulation and tumor destruction in mice harboring lung cancer	34
Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapy	32
Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity	31
Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia	29

Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T	28
CircRHBDD1 augments metabolic rewiring and restricts immunotherapy efficacy via m6A modification in hepatocellular carcinoma	27
A library of cancer testis specific T cell receptors for T cell receptor gene therapy	27
Intraperitoneal oncolytic virotherapy for patients with malignant ascites: Characterization of clinical efficacy and antitumor immune response	27
The role and application of vesicles in triple-negative breast cancer: Opportunities and challenges	27
Oncolytic adenovirus-mediated expression of decorin facilitates CAIX-targeting CAR-T therapy against renal cell carcinoma	27